ERBB2 and breast carcinoma: Nonetheless, the observation of significantly increased PFS in patients from BELLE-2 and BELLE-3 trials who had PIK3CA genetic alterations supports the rationale for PI3K inhibition plus endocrine therapy in HR+/HER2– Luminal A breast cancer patients.